Get the Stockscreener App
14.88
2.49%
-0.38
After Hours:
14.80
-0.08
-0.54%
Contineum Therapeutics Inc stock is traded at $14.88, with a volume of 93,776.
It is down -2.49% in the last 24 hours and up +62.27% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$15.26
Open:
$15.26
24h Volume:
93,776
Relative Volume:
0.39
Market Cap:
$543.56M
Revenue:
-
Net Income/Loss:
$-35.46M
P/E Ratio:
-35.28
EPS:
-0.4218
Net Cash Flow:
$-34.00M
1W Performance:
+2.76%
1M Performance:
+62.27%
6M Performance:
+120.44%
1Y Performance:
+91.01%
1-Day Range:
$14.59
$15.36
1-Week Range:
$13.86
$16.01
52-Week Range:
$3.35
$16.01
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
14.88 | 557.44M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - MSN
Entry Recap: How sensitive is Contineum Therapeutics Inc to inflationQuarterly Earnings Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Franklin Resources Inc. Expands Holdings in Contineum Therapeuti - GuruFocus
Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Trend Review: Is SFBS a top pick in the sectorOptions Play & AI Driven Stock Price Forecasts - baoquankhu1.vn
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 28, 2026 - BioSpace
Contineum Therapeutics reports inducement grant under Nasdaq Listing Rule - marketscreener.com
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule - TradingView
Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutions - Yahoo Finance
Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan - TipRanks
Big Money Moves: Will Contineum Therapeutics Inc stock recover after earningsMarket Performance Recap & High Conviction Trade Alerts - baoquankhu1.vn
Aug EndMonth: Is Contineum Therapeutics Inc currently under institutional pressureWeekly Trend Summary & Long-Term Capital Growth Strategies - baoquankhu1.vn
Take Profit: Will Contineum Therapeutics Inc stock recover after earningsJuly 2025 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Contineum Therapeutics Reports Phase 2 Trial Results - MSN
Aug Swings: Why Contineum Therapeutics Inc. stock attracts high net worth investorsJuly 2025 Gainers & Daily Momentum Trading Reports - moha.gov.vn
Growth Review: Is Contineum Therapeutics Inc stock overvalued or fairly priced2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - baoquankhu1.vn
Market Recap: How interest rate cuts could boost Contineum Therapeutics Inc stock2025 Trading Volume Trends & Fast Entry High Yield Tips - Bộ Nội Vụ
Contineum Therapeutics stock drops as company prices upsized $90 million offering - MSN
Why retail investors favor Contineum Therapeutics Inc. stockDip Buying & Safe Entry Point Identification - ulpravda.ru
What risks investors should watch in Contineum Therapeutics Inc. stockInflation Watch & Reliable Intraday Trade Alerts - Улправда
Contineum Therapeutics (NASDAQ:CTNM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Receives Equal Weight Rating from Morgan Stanley - Defense World
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley - TipRanks
How interest rate cuts could boost Contineum Therapeutics Inc. stockJuly 2025 Setups & Safe Entry Trade Signal Reports - Улправда
What hedge fund activity signals for Contineum Therapeutics Inc. stockTrade Risk Report & AI Enhanced Execution Alerts - Улправда
How Contineum Therapeutics Inc. stock compares to market leaders2025 Market WrapUp & AI Driven Stock Movement Reports - ulpravda.ru
Stock Market Recap: How currency fluctuations impact Contineum Therapeutics Inc stock2025 Market Trends & Short-Term High Return Ideas - moha.gov.vn
Should I hold or sell Contineum Therapeutics Inc. stock in 2025July 2025 Closing Moves & Safe Entry Momentum Tips - Улправда
Setup Watch: How interest rate cuts could boost Contineum Therapeutics Inc. stockGold Moves & Weekly Top Performers Watchlists - Улправда
Can Contineum Therapeutics Inc. stock maintain operating marginsQuarterly Portfolio Report & Fast Moving Stock Trade Plans - ulpravda.ru
CTNM: Morgan Stanley Downgrades with Lowered Price Target | CTNM Stock News - GuruFocus
Contineum Therapeutics (NASDAQ:CTNM) Earns "Equal Weight" Rating from Morgan Stanley - MarketBeat
Morgan Stanley Downgrades Contineum Therapeutics to Equalweight From Overweight, Adjusts Price Target to $14 From $23 - marketscreener.com
Contineum Therapeutics stock downgraded by Morgan Stanley on IPF drug concerns - Investing.com Nigeria
What sentiment indicators say about Contineum Therapeutics Inc. stockSector Performance Review & Explosive Capital Gains - Улправда
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? - Finviz
Lorrain, Contineum Therapeutics CSO, sells $51k in stock - Investing.com India
Lorrain, Contineum Therapeutics CSO, sells $51k in stock By Investing.com - Investing.com Australia
Contineum Therapeutics announces proposed $75M public offering - MSN
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):